One out of every three deaths in the United States is accorded to cardiovascular diseases 0 including heart disease and stroke. It has turned out to be the leading cause of death in the country.
Every year, over 800,000 deaths occur in the country due to cardiovascular diseases according to figures from the American Heart Association. It also states that the after effects of a stroke or at least one type of cardiovascular disease is ailing at least 92 million Americans.
America’s biopharmaceutical companies are presently working on the development of at least 200 medicines related to treatment and prevention of cardiovascular diseases.
However, the aspect of prevention, diagnosis and treatment of cardiovascular disease has assumed significant importance in the U.S. and there has been very good progress in this matter in recent years in the country despite the alarming figures. People who suffer from heart diseases are being aided to line longer and healthier lives because of significant advancement in treatment in addition to enhanced awareness and education about leading healthy lifestyle and changes in life behavior.
According to a new report, the U.S. based pharma companies are developing 42 medicines related to heart failure, 23 medicines to cope with stroke and 14 for hypertension and high blood pressure among the 200 new medicines that are at various stages of development currently.
There are also a number of novel approaches for treatment of cardiovascular diseases that are included in the above list of cardiovascular medicine development.
The new approaches for treatment of cardiovascular diseases include treatment for coronary artery disease. Pharma companies are in the process of developing a medicine – currently in its clinical trial phase, for potentially reducing significant cardiac incidents like a heart attack or stroke. This approach is aimed for people who have suffer from coronary artery disease, type 2 diabetes and low levels of "good" cholesterol.
Another important medicine being developed is for heart failure. This is based on a non-viral gene therapy and is being currently developed. It would be used for treatment of ischemic heart failure. The approach would target a tissue repair and regeneration pathway in the human body.
Stroke is another cardiovascular disease for which treatment and medicine is being further developed. Pharma companies are testing a novel treatment method that would potentially have the capacity to repair brain damage that occurs due to a stroke.
(Source:www.prnewswire.com)
Every year, over 800,000 deaths occur in the country due to cardiovascular diseases according to figures from the American Heart Association. It also states that the after effects of a stroke or at least one type of cardiovascular disease is ailing at least 92 million Americans.
America’s biopharmaceutical companies are presently working on the development of at least 200 medicines related to treatment and prevention of cardiovascular diseases.
However, the aspect of prevention, diagnosis and treatment of cardiovascular disease has assumed significant importance in the U.S. and there has been very good progress in this matter in recent years in the country despite the alarming figures. People who suffer from heart diseases are being aided to line longer and healthier lives because of significant advancement in treatment in addition to enhanced awareness and education about leading healthy lifestyle and changes in life behavior.
According to a new report, the U.S. based pharma companies are developing 42 medicines related to heart failure, 23 medicines to cope with stroke and 14 for hypertension and high blood pressure among the 200 new medicines that are at various stages of development currently.
There are also a number of novel approaches for treatment of cardiovascular diseases that are included in the above list of cardiovascular medicine development.
The new approaches for treatment of cardiovascular diseases include treatment for coronary artery disease. Pharma companies are in the process of developing a medicine – currently in its clinical trial phase, for potentially reducing significant cardiac incidents like a heart attack or stroke. This approach is aimed for people who have suffer from coronary artery disease, type 2 diabetes and low levels of "good" cholesterol.
Another important medicine being developed is for heart failure. This is based on a non-viral gene therapy and is being currently developed. It would be used for treatment of ischemic heart failure. The approach would target a tissue repair and regeneration pathway in the human body.
Stroke is another cardiovascular disease for which treatment and medicine is being further developed. Pharma companies are testing a novel treatment method that would potentially have the capacity to repair brain damage that occurs due to a stroke.
(Source:www.prnewswire.com)
